Biomin Financing to Fund Distribution of Pharmaceuticals and Mineral/Vitamin Supplements in Mexico.

Therapeutic Corporation (CANADIAN DEALING NETWORK: BMIN) announces that it reached agreement, subject to formal documentation, to acquire 100 percent of the outstanding shares of Pharmex Industries Inc., a distributor of Canadian-made over-the-counter (OTC) pharmaceuticals and mineral and vitamin supplements in Mexico.

Pharmex was established in the summer of 1995 and shortly thereafter was appointed the exclusive agent of Stanley Pharmaceuticals Ltd. of Vancouver, a member of the Novopharm group of companies, to bulk purchase for registration, distribution, packaging, marketing and sale into Mexico 120 such products. All of these products have been approved by the Canadian Health Protection Branch for distribution in Canada. As a result, these products meet regulatory specifications for distribution in Mexico, and qualify for fast-track approval for Mexican distribution by the Mexican Minister of Health (the SSA).

Pharmex, through its Mexican subsidiary, has commenced the launch of its initial product line of seven OTC pharmaceuticals and vitamin and mineral supplements, manufactured by Stanley, and packaged and sold under the Pharmex label, through major Mexican distributors. The next phase of Pharmex' marketing, scheduled to commence in the spring of 1996, will be "generic", private-label product through major Mexican retail chains. The third phase will be under the Pharmex label into the hospital and government market in Mexico. Ultimately, Pharmex plans to expand its product sales into other Latin American countries.

Pharmex' strategy is to exploit the fact that there is virtually no generic-brand distribution of similar products in Mexico, and to provide a broader supply of lower-cost, higher-quality pharmaceuticals and vitamin and mineral supplements than is currently available, i.e. U.S. manufactured, packaged and imported products with limited distribution.

With financing provided by a third-party $330,000 loan in late 1995, Pharmex established a packaging facility in Hermosillo, Mexico that has received full regulatory approval of the Mexican SSA. Pharmex plans to upgrade the facility to a manufacturing plant in mid-1996.

Based on a review of market data, prices of products currently available in Mexico and Pharmex' estimated product, packaging and distribution costs, the Company believes that Pharmex' products will retail in Mexico at significantly lower prices than competing products, while providing improved margins for the distributors and retail outlets and generating minimum profit margins of 100 percent for Pharmex.

Pharmex has not generated any product sales to date. Assets on its current balance sheet include capital assets carried at a value of $100,000, deferred development costs of approximately $220,000 and inventories of $60,000. Liabilities include the $330,000 long-term loan described herein, accounts payable of approximately $40,000 and share capital of approximately $10,000.

Biomin, currently inactive, was previously engaged in funding research and development of orally-administered gallium pharmaceuticals. Biomin has entered into agreements with the shareholders of Pharmex, all of whom are at arm's length to Biomin, pursuant to which such shareholders have agreed to sell to Biomin all of the outstanding shares of Pharmex in consideration for the payment of $250,000 to the selling shareholders. Biomin will make such payments from the proceeds of $450,000 from a recently-completed private placement of 9,000,000 units at a price of $0.05 per unit, each unit consisting of one common share and one-half of a warrant, each whole warrant entitling the holder to purchase a common share of Biomin at a price of $0.10 for a period of one year.

Ahmad Doroudian will be appointed President and CEO of Biomin and Andrew Small will be appointed Chief Financial Officer of Biomin. Mr. Doroudian, currently director of operations of Pharmex, obtained a Masters of Sciences degree in pharmaceutical sciences, specializing in industrial pharmacy, from the University of British Columbia. Until recently, Mr. Doroudian was Manager of Manufacturing for Stanley Pharmaceuticals and for the last three years has been President and CEO of Pharmex Rom Industry SRL, which was established by Mr. Doroudian in 1992 to carry out a similar business to Pharmex in Romania. Mr. Small, currently director of finance and administration of Pharmex, is a Chartered Accountant involved primarily in small business management and finance, with two years' experience in Mexico. Donald R. Sheldon, a director of the Company, will be appointed Chairman of Biomin.

CONTACT: Biomin Therapeutic Corporation

Donald R. Sheldon, 604/687-2038